| Identification | Back Directory | [Name]
JWH 203 N-(4-hydroxypentyl) metabolite | [CAS]
1843184-38-2 | [Synonyms]
ALUOSHHIHVCMCU-UHFFFAOYSA-N
JWH 203 N-(4-hydroxypentyl) metabolite | [Molecular Formula]
C21H22ClNO2 | [MOL File]
1843184-38-2.mol | [Molecular Weight]
355.86 |
| Chemical Properties | Back Directory | [Boiling point ]
543.0±40.0 °C(Predicted) | [density ]
1.19±0.1 g/cm3(Predicted) | [solubility ]
DMF: 10 mg/ml; DMSO: 5 mg/ml | [pka]
15.19±0.20(Predicted) |
| Hazard Information | Back Directory | [Description]
JWH 203 is an analgesic chemical from the phenylacetylindole family that acts as a cannabinoid (CB) agonist with Ki values of 8.0 and 7.0 nM at the central (CB1) and peripheral (CB2) CB receptors, respectively. Similar to the related 2''-methoxy compound JWH 250 , JWH 203 has a phenylacetyl group in place of the naphthoyl ring used in most aminoalkylindole cannabinoid compounds. Compared to JWH 250, JWH 203 displays slightly more potent binding affinities for the CB1 and CB2 CB receptors (JWH 250 Kis = 11 and 33 nM, respectively). JWH 203 N-(4-hydroxypentyl) metabolite is expected to be a metabolite of JWH 203 that would be detectable both in serum and in urine. While similar hydroxylated phase I metabolites of synthetic CB retain activity, the physiological properties of this compound have yet to be determined. This product is intended for research and forensic applications. | [Uses]
JWH 203 is an analgesic chemical from the phenylacetylindole family that acts as a cannabinoid (CB) agonist with Ki values of 8.0 and 7.0 nM at the central (CB1) and peripheral (CB2) CB receptors, respectively. Similar to the related 2'-methoxy compound JWH 250 , JWH 203 has a phenylacetyl group in place of the naphthoyl ring used in most aminoalkylindole cannabinoid compounds. Compared to JWH 250, JWH 203 displays slightly more potent binding affinities for the CB1 and CB2 CB receptors (JWH 250 Kis = 11 and 33 nM, respectively). JWH 203 N-(4-hydroxypentyl) metabolite is expected to be a metabolite of JWH 203 that would be detectable both in serum and in urine. While similar hydroxylated phase I metabolites of synthetic CB retain activity, the physiological properties of this compound have yet to be determined. This product is intended for research and forensic applications.[Cayman Chemical] | [References]
[1] LISA K BRENTS. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.[J]. PLoS ONE, 2011: e21917. DOI: 10.1371/journal.pone.0021917
[2] LISA K. BRENTS . Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity[J]. Biochemical pharmacology, 2012, 83 7: Pages 952-961. DOI: 10.1016/j.bcp.2012.01.004 |
|
|